Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.

Gleeson, M; Counsell, N; Cunningham, D; Chadwick, N; Lawrie, A; Hawkes, E; McMillan, A; Ardeshna, K; Jack, A; Smith, P; Mouncey, P; Pocock, C; Radford, John A; Davies, J; Turner, D; Kruger, A; Johnson, P; Gambell, J; Linch, D

dc.contributor.author	Gleeson, M
dc.contributor.author	Counsell, N
dc.contributor.author	Cunningham, D
dc.contributor.author	Chadwick, N
dc.contributor.author	Lawrie, A
dc.contributor.author	Hawkes, E
dc.contributor.author	McMillan, A
dc.contributor.author	Ardeshna, K
dc.contributor.author	Jack, A
dc.contributor.author	Smith, P
dc.contributor.author	Mouncey, P
dc.contributor.author	Pocock, C
dc.contributor.author	Radford, John A
dc.contributor.author	Davies, J
dc.contributor.author	Turner, D
dc.contributor.author	Kruger, A
dc.contributor.author	Johnson, P
dc.contributor.author	Gambell, J
dc.contributor.author	Linch, D
dc.date.accessioned	2017-10-19T19:59:27Z
dc.date.available	2017-10-19T19:59:27Z
dc.date.issued	2017-10-01
dc.identifier.citation	Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. 2017, 28 (10):2511-2516 Ann Oncol	en
dc.identifier.issn	1569-8041
dc.identifier.pmid	28961838
dc.identifier.doi	10.1093/annonc/mdx353
dc.identifier.uri	http://hdl.handle.net/10541/620599
dc.description	Lymphoma Research Team	en
dc.description.abstract	Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a dismal prognosis. Here, we report an analysis of CNS relapse for patients treated within the UK NCRI phase III R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) 14 versus 21 randomised trial.
dc.language.iso	en	en
dc.rights	Archived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology	en
dc.title	Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.	en
dc.type	Article	en
dc.contributor.department	Department of Medicine, The Royal Marsden Hospital, London and Surrey, UK	en
dc.identifier.journal	Annals of Oncology	en
refterms.dateFOA	2018-12-17T15:04:31Z
html.description.abstract	Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a dismal prognosis. Here, we report an analysis of CNS relapse for patients treated within the UK NCRI phase III R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) 14 versus 21 randomised trial.